[{"Assets_0_Q3_USD":257038000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":59187000.0,"NetIncomeLoss_1_Q3_USD":-2390000.0,"NetIncomeLoss_3_Q3_USD":13308000.0,"StockholdersEquity_0_Q3_USD":175765000.0,"EarningsPerShareBasic_1_Q3_USD":-0.17,"EarningsPerShareBasic_3_Q3_USD":0.96,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":13668091.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":13791071.0,"Ticker":"EGRX","CIK":"827871","name":"EAGLE PHARMACEUTICALS, INC.","OfficialName":"Eagle Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20190930","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"635235963.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20191112"}]